Xifaxan Tablet
Product Images NDC 55154-6777

6 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Xifaxan (NDC 55154-6777). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem Structure (Image 01)

Chem Structure (Image 01)
Chemical structure of rifaximin, the active ingredient in XIFAXAN 550 mg oral tablets by Cardinal Health 107, LLC. The diagram depicts the molecular arrangement and bonding of rifaximin.*
FDA Label Image

Graph 1 (Image 02)

Graph 1 (Image 02)
A Kaplan-Meier survival curve chart depicting the proportion of patients without breakthrough HE (hepatic encephalopathy) over 168 days post-randomization. The chart compares XIFAXAN and placebo groups, showing a higher sustained proportion for XIFAXAN. The figure includes hazard ratio, 95% confidence interval, and p-value statistics.*
FDA Label Image

Graph2 (Image 03)

Graph2 (Image 03)
A Kaplan-Meier plot showing the proportion of patients without HE-related hospitalization over days post-randomization, comparing XIFAXAN 550 mg tablets to placebo. The y-axis represents the proportion of patients without hospitalization, and the x-axis shows days post-randomization up to 168 days. The graph includes hazard ratio, confidence interval, and log-rank p-value statistics in a boxed inset.*
FDA Label Image

Graph 3 (Image 04)

Graph 3 (Image 04)
A clinical study flow diagram showing phases for a treatment involving placebo (PBO) and rifaximin (RFX). It includes Screening/Treatment 1 Phase, Treatment 2 Phase (2 weeks RFX, 4 weeks follow-up), Maintenance Phase 1 (up to 18 weeks), randomization into Treatment 3 Phase/DBR Treatment Phase, Maintenance Phase 2 (6 weeks), Treatment 4 Phase/SRT Phase, and Follow-up (4 weeks). The diagram highlights symptom diary collection and primary efficacy analysis periods.*
FDA Label Image

Study (Image 07)

Study (Image 07)
A clinical trial study timeline diagram showing multiple phases including Screening/Treatment 1, Treatment 2 Phase, Maintenance Phase 1, Treatment 3 Phase/DBR Treatment Phase, Maintenance Phase 2, Treatment 4 Phase/SRT Phase, and Follow-up. It outlines study day 1 to end of study (EOS), detailing treatment with Rifaximin (RFX) or placebo (PBO) at different intervals, follow-up periods, primary evaluation period, randomization, and symptom diary collection.*
FDA Label Image

550mg Bottle Label (3867f2d4 D171 936b E063 6394a90a6008 00)

550mg Bottle Label (3867f2d4 D171 936b E063 6394a90a6008 00)
Label for XIFAXAN (rifaximin) tablets, 550 mg, oral dosage form. The label states each tablet contains 550 mg of rifaximin. It includes storage instructions, pharmacist dispensing guidance, and a warning to keep out of reach of children. The labeler is Cardinal Health 107, LLC, with product NDC 55154-6777. The label also features barcodes and manufacturing details by Astellas Pharma USA, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.